Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peripheral T-cell lymphoma

Peripheral T-cell lymphoma

Part of Non-Hodgkin's Lymphoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peripheral T-cell lymphoma

50 trials tracked for Peripheral T-cell lymphoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 35 citations.

50Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 2 40 Phase 1 6 Other / NA 3
  1. Phase 4 Treatment of Peripheral T-cell Lymphoma Completed · 35 cited
  2. Phase 2 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma Completed
  3. Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
  4. Phase 2 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Completed
  5. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  6. Phase 2 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed
Show 44 more trials
  1. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  2. Phase 2 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed
  3. Phase 2 A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Completed
  4. Phase 2 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed
  5. Phase 2 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides Completed
  6. Phase 2 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Completed
  7. Phase 2 Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Completed
  8. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  9. Phase 2 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Completed
  10. Phase 2 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed
  11. Phase 2 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Completed
  12. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  13. Phase 2 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed
  14. Phase 2 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Completed
  15. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  16. Phase 2 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed
  17. Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Completed
  18. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  19. Phase 2 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Completed
  20. Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed
  21. Phase 2 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma Completed
  22. Phase 2 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Completed
  23. Phase 2 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Completed
  24. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  25. Phase 2 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Completed
  26. Phase 2 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Completed
  27. Phase 2 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Completed
  28. Phase 2 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed
  29. Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  30. Phase 2 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Completed
  31. Phase 2 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed
  32. Phase 2 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Completed
  33. Phase 2 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed
  34. Phase 2 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Completed
  35. Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  36. Phase 1 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Completed
  37. Phase 1 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Completed
  38. Phase 1 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Completed
  39. Phase 1 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed
  40. Phase 1 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed
  41. Phase 1 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed
  42. N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed
  43. N/A High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Completed
  44. N/A Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
Oncology Phase I
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Apr 12, 2026

Research across Non-Hodgkin's Lymphoma

Related studies from across the Non-Hodgkin's Lymphoma family.

OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Hematology Meta-analysis
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Jun 1, 2026
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
Allergy & Immunology Sys. Review
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Frontiers May 29, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
Drug Pipeline Sys. Review
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
Frontiers May 9, 2026
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
Oncology FDA Approval
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
FDA May 5, 2026
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
Oncology Meta-analysis
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
May 3, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
Oncology RCT
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis New Drug Cuts Severe Infection Risk In Lymphoma Care
This randomized controlled trial evaluated mecapegfilgrastim in 42 treatment-naive patients with diffuse large B-cell lymphoma.
A new long-acting injection lowers the risk of dangerous low white blood cell counts in lymphoma patients starting their first round of chem…
May 1, 2026